向日葵(300111.SZ):子公司貝得藥業與龍華建設簽訂440萬元淨化裝飾與機電安裝工程合同
格隆匯 10 月 15日丨向日葵(300111.SZ)公佈,2020年10月14日,公司控股子公司浙江貝得藥業有限公司(簡稱“貝得藥業”)與浙江龍華新世紀房地產開發有限公司(簡稱“龍華房產”)全資子公司紹興龍華建設有限公司(簡稱“龍華建設”)簽訂《淨化裝飾與機電安裝工程合同書》,合同施工總工期預估90天,施工合同總價款為440萬元。
貝得藥業是公司的控股子公司,公司的實際控制人為吳建龍,貝得藥業為公司控股子公司。龍華建設為浙江龍華新世紀房地產開發有限公司全資子公司,龍華房產為公司實際控制人吳建龍控制的公司,根據《深圳證券交易所創業板股票上市規則》的相關規定,龍華建設為公司的關聯方,本次交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.